article thumbnail

FDA Accepts for Review Pfizer’s Supplemental Application for ABRILADA™ (adalimumab-afzb) Interchangeability

The Pharma Data

Food and Drug Administration (FDA) has accepted for review the Prior Approval Supplement (PAS) to the Biologics License Application (BLA) for ABRILADA™ (adalimumab-afzb) as an interchangeable biosimilar to Humira® (adalimumab). Pfizer Inc. NYSE: PFE) today announced that the U.S.

article thumbnail

Top 30 Pharma and Biotech Companies in 2023: Statistics and Trends

XTalks

2) Paxlovid (nirmatrelvir/ritonavir) Paxlovid is a dual-packaged oral medication for the treatment of COVID-19. a month for either 150 mg or 300 mg dose strength packages, and $3,462.13 for the 75 mg dose strength package in January 2023, according to the manufacturer. Total global revenue from Cosentyx was $4.79

Sales 98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Amgen Reports Second Quarter 2021 Financial Results

The Pharma Data

We expect that recovery in the dermatology segment will continue to progress over the coming quarters. In July, the FDA accepted the Biologics License Application and granted Priority Review for tezepelumab for the treatment of asthma. and continued geographic expansion, including the launch in China. Tezepelumab.

Sales 52
article thumbnail

Pharma Marketing Network - Untitled Article

Pharma Marketing Network

So a doctor that’s licensed stay only in the state of New York would be able to practice across the entire counties using Telemedicine.

Insulin 52
article thumbnail

Pharma Marketing Network - Untitled Article

Pharma Marketing Network

So a doctor that’s licensed stay only in the state of New York would be able to practice across the entire counties using Telemedicine.

Insulin 52